<i>CREBBP</i> knockdown suppressed proliferation and promoted chemo-sensitivity via PERK-mediated unfolded protein response in ovarian cancer

Hu, Haoyang; Yin, Sheng; Ma, Ruyue; Chen, Rujun; Liu, Shuqing; Chen, Yaping; He, Fei; Yang, Lina

doi:10.7150/jca.56135

Cited by 9 publications

(5 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, our findings also revealed that high CREBBP expression was associated with a favorable HNSCC prognosis, indicating that CREBBP might play a tumor-suppressive role in HNSCC. However, Hu et al demonstrated that CREBBP acted as an oncogene and predicted a poor prognosis in ovarian cancer [ 37 ]. These differences might be due to tumor heterogeneity among different malignancies.…”

Section: Discussionmentioning

confidence: 99%

Development and Validation of a Prognostic Signature Based on the Lysine Crotonylation Regulators in Head and Neck Squamous Cell Carcinoma

Jiang

Yin

Zhang

et al. 2023

BioMed Research International

View full text Add to dashboard Cite

Background. Lysine crotonylation (Kcr) is a newly identified posttranslational modification type regulated by various enzymes and coenzymes, including lysine crotonyltransferase, lysine decrotonylase, and binding proteins. However, the role of Kcr regulators in head and neck squamous cell carcinoma (HNSCC) remains unknown. The aim of this study was to establish and validate a Kcr-related prognostic signature of HNSCC and to assess the clinical predictive value of this signature. Methods. The mRNA expression profiles and clinicopathological data from The Cancer Genome Atlas (TCGA) database were downloaded to explore the clinical significance and prognostic value of these regulators in HNSCC. The least absolute shrinkage and selection operator (LASSO) Cox regression model was used to generate the Kcr-related prognostic signature for HNSCC. Subsequently, the GSE65858 dataset from the Gene Expression Omnibus (GEO) database was used to validate the signature. The prognostic value of the signature was evaluated using the Kaplan-Meier survival, receiver operating characteristic (ROC) curve, and univariate and multivariate Cox regression analyses. Results. We established a nine-gene risk signature associated with the prognosis of HNSCC based on Kcr regulators. High-risk patients demonstrated significantly poorer overall survival (OS) than low-risk patients in the training (TCGA) and validation (GEO) datasets. Then, the time-dependent receiver operating characteristic (ROC) curve analysis showed that the nine-gene risk signature was more accurate for predicting the 5-year OS than other clinical parameters, including age, gender, T stage, N stage, and histologic grade in the TCGA and GEO datasets. Moreover, the Cox regression analysis showed that the constructed risk signature was an independent risk factor for HNSCC. Conclusion. Our study identified and validated a nine-gene signature for HNSCC based on Kcr regulators. These results might contribute to prognosis stratification and treatment escalation for HNSCC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Development and Validation of a Prognostic Signature Based on the Lysine Crotonylation Regulators in Head and Neck Squamous Cell Carcinoma

Jiang

Yin

Zhang

et al. 2023

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Among OCCC CNV gains events, ARID1B, ARID1A1, and ASXL1 are associated with chromatin remodeling and modification. In novel identified CNV events of OCCC, CREBBP is involved in tumorigenesis in various cancers, and knockdown CREBBP can promote chemo-sensitivity in ovarian cancer cells ( Hu et al, 2021 ), while EPHA2 is associated with platinum-resistant in HGSOC, and RSK inhibitors effectively sensitized cells with EphA2 high to the therapy-induced apoptosis ( Moyano-Galceran et al, 2020 ), LRP1B can act as a predictor of response to pegylated liposomal doxorubicin for ovary cancer ( Dionisio de Sousa et al, 2021 ). These results provided more potential targets for OCCC treatment.…”

Section: Discussionmentioning

confidence: 99%

Next-generation sequencing shows the genomic features of ovarian clear cell cancer and compares the genetic architectures of high-grade serous ovarian cancer and clear cell carcinoma in ovarian and endometrial tissues

Gan

Tai

et al. 2023

PeerJ

View full text Add to dashboard Cite

Ovarian clear cell carcinoma (OCCC) is a special histological type of epithelial ovarian cancer (EOC) that is not derived from epithelial cells of the ovarian or fallopian tube as the most common type of ovarian cancer, high-grade serous ovarian carcinoma (HGSOC), but is closely related to endometriosis and similar to endometrial clear cell carcinoma (ECCC) at morphologic and phenotypic features. However, limited data was shown in OCCC genomic features and compared with that in OCCC, HGSOC and ECCC. Herein, we utilized next-generation sequencing analysis of a panel of 1,021 genes to profile the mutational alterations in 34 OCCC and compared them to those from HGSOC (402 cases) and ECCC (30 cases). In result, the ARID1A and PIK3CA are high-frequency mutations of OCCC. Clonal architectures showed that all the mutations of genes occur in the later stage in the OCCC progress, whereas KRAS mutation is the earlier event compared with mutation of ARID1A or PIK3CA, which usually occurs in a group of ARID1A or PIK3CA mutations. The mutation frequency of main driver genes is similar between OCCC and ECCC, while TP53 is the main mutation in HGSOC and ECCC. Shared mutational signatures between OCCC and ECCC tissues with commonly observed a C>T change indicated a common carcinogens-exposed between these two carcinomas, but HGSOC and ECCC have common and distinct mutational signatures across cohorts respectively. In addition, we identified some novel CNV gains in NF1, ASXL1, TCF7L2, CREBBP and LRP1B and loss in ATM, FANCM, RB1 and FLT in OCCC. Our study offered a new perspective for OCCC tumorigenesis from two organs, the ovary and uterus, at genomic architectures and revealed novel CNV events for helping to provide theoretical support for OCCC treatment.

show abstract

“…SLC9A2 (solute carrier family 9, member 2 of subfamily A) has been reported to be drug resistant in OC cell lines [ 42 ]. STC2 (stanniocalcin 2) has been reported to participate in tumor proliferation in vitro and in vivo [ 43 ]. TBP (TATA box binding protein) has been reported to participate in the transcriptional regulation of OC [ 44 ].…”

Section: Discussionmentioning

confidence: 99%

A novel DNA methylation-related gene signature for the prediction of overall survival and immune characteristics of ovarian cancer patients

Wang

Fang

2023

J Ovarian Res

View full text Add to dashboard Cite

Background Ovarian cancer (OC) is one of the most life-threatening cancers affecting women worldwide. Recent studies have shown that the DNA methylation state can be used in the diagnosis, treatment and prognosis prediction of diseases. Meanwhile, it has been reported that the DNA methylation state can affect the function of immune cells. However, whether DNA methylation-related genes can be used for prognosis and immune response prediction in OC remains unclear. Methods In this study, DNA methylation-related genes in OC were identified by an integrated analysis of DNA methylation and transcriptome data. Prognostic values of the DNA methylation-related genes were investigated through least absolute shrinkage and selection operator (LASSO) and Cox progression analyses. Immune characteristics were investigated by CIBERSORT, correlation analysis and weighted gene co-expression network analysis (WGCNA). Results Twelve prognostic genes (CA2, CD3G, HABP2, KCTD14, PI3, SERPINB5, SLAMF7, SLC9A2, STC2, TBP, TREML2 and TRIM27) were identified and a risk score signature and a nomogram based on prognostic genes and clinicopathological features were constructed for the survival prediction of OC patients in the training and two validation cohorts. Subsequently, the differences in the immune landscape between the high- and low-risk score groups were systematically investigated. Conclusions Taken together, our study explored a novel efficient risk score signature and a nomogram for the survival prediction of OC patients. In addition, the differences of the immune characteristics between the two risk groups were clarified preliminarily, which will guide the further exploration of synergistic targets to improve the efficacy of immunotherapy in OC patients.

show abstract

CREBBP knockdown suppressed proliferation and promoted chemo-sensitivity via PERK-mediated unfolded protein response in ovarian cancer

Cited by 9 publications

References 34 publications

Development and Validation of a Prognostic Signature Based on the Lysine Crotonylation Regulators in Head and Neck Squamous Cell Carcinoma

Development and Validation of a Prognostic Signature Based on the Lysine Crotonylation Regulators in Head and Neck Squamous Cell Carcinoma

Next-generation sequencing shows the genomic features of ovarian clear cell cancer and compares the genetic architectures of high-grade serous ovarian cancer and clear cell carcinoma in ovarian and endometrial tissues

A novel DNA methylation-related gene signature for the prediction of overall survival and immune characteristics of ovarian cancer patients

Contact Info

Product

Resources

About